Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck

Inclusion Criteria: * Any patient who is eligible for definitive curative radio-chemotherapy with Cisplatin or radio-immunotherapy with Cetuximab. * Written informed consent obtained prior to any study specific screening activities and patients have to be able to comply with this protocol. * Histologically confirmed local advanced squamous cell carcinoma of the Larynx, Hypopharynx, Oropharynx or Cavum oris treated with definitive radiotherapy in combination with Cisplatin or Cetuximab. * p16 status available * Age ≥ 18 * Women of childbearing potential must have a negative pregnancy test at screening and must use effective contraception. Exclusion Criteria: * Distant metastases * Prior radiation (Head and neck area) * Pregnant or lactating women * History of other malignancy; yet patients who have been disease-free for 5 years or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. * Concurrent other cancer therapy (chemotherapy, immunotherapy, antihormonal or biologic therapy) or concurrent treatment with an investigational drug. * Serious medical or psychiatric disorders that would interfere with the patient's safety or informed consent. * Participation in another interventional clinical study at time of study inclusion (except follow-up period without treatment for more than 30 days) or denial of the simultaneous participation in a non-interventional study by the PI of the study center.